DIRS.INFO The most relevant business & tech news

☆ 2023 was a tough year for us, but we expect a rebound in 2024: Takeda Pharmaceuticals CEO
▼ + stars: | 2024-02-02 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via Email2023 was a tough year for us, but we expect a rebound in 2024: Takeda Pharmaceuticals CEOChristophe Weber, CEO of Takeda Pharmaceuticals says product pipeline was very positive in the last quarter and shares his business outlook for 2024.

Persons: Christophe Weber, Takeda Organizations: Takeda, Takeda Pharmaceuticals

☆ Dengue Will 'Take Off' in Southern Europe, US, Africa This Decade, WHO Scientist Says
▼ + stars: | 2023-10-06 | by ( Oct. | At A.M. | ) www.usnews.com time to read: +4 min

By Jennifer RigbyLONDON (Reuters) - Dengue fever will become a major threat in the southern United States, southern Europe and new parts of Africa this decade, the WHO's chief scientist said, as warmer temperatures create the conditions for the mosquitoes carrying the infection to spread. Many cases go unrecorded, but in 2022 4.2 million cases were reported worldwide and public health officials have warned that near-record levels of transmission are expected this year. Earlier this week, the WHO recommended Takeda Pharmaceuticals' Qdenga vaccine for children aged 6 to 16 in areas where the infection is a significant public health problem. Qdenga is also approved by the EU regulator, but Takeda withdrew its application in the United States earlier this year, citing data collection issues. Dengue is spread by infected Aedes aegypti mosquitoes, which behave differently to the malaria-carrying kind.

Persons: Jennifer Rigby LONDON, ” Jeremy Farrar, ” Farrar, Farrar, ”, “, Takeda, Jennifer Rigby, Michele Gershberg, Sharon Singleton Organizations: World Health Organization, Reuters, Wellcome, WHO, Takeda Pharmaceuticals, U.S . Food, Drug Administration Locations: United States, Europe, Africa, Asia, Latin America, Bangladesh, Vietnam, Saharan Africa, EU

[1/2] Mosquitoes are seen on stagnant water on the roadside during countrywide dengue infection, in Dhaka, Bangladesh, August 24, 2023. REUTERS/Mohammad Ponir Hossain/File Photo Acquire Licensing RightsCompanies Takeda Pharmaceutical Co Ltd FollowLONDON, Oct 6 (Reuters) - Dengue fever will become a major threat in the southern United States, southern Europe and new parts of Africa this decade, the WHO's chief scientist said, as warmer temperatures create the conditions for the mosquitoes carrying the infection to spread. Many cases go unrecorded, but in 2022 4.2 million cases were reported worldwide and public health officials have warned that near-record levels of transmission are expected this year. Qdenga is also approved by the EU regulator, but Takeda withdrew its application in the United States earlier this year, citing data collection issues. Dengue is spread by infected Aedes aegypti mosquitoes, which behave differently to the malaria-carrying kind.

Persons: Mohammad Ponir Hossain, ” Jeremy Farrar, ” Farrar, Farrar, ”, “, Takeda, Jennifer Rigby, Michele Gershberg, Sharon Singleton Organizations: REUTERS, Takeda Pharmaceutical, World Health Organization, Reuters, Wellcome, WHO, Takeda Pharmaceuticals, U.S . Food, Drug Administration, Thomson Locations: Dhaka, Bangladesh, United States, Europe, Africa, Asia, Latin America, Vietnam, Saharan Africa, EU

A nurse fills a syringe with malaria vaccine before administering it to an infant at the Lumumba Sub-County hospital in Kisumu, Kenya, July 1, 2022. REUTERS/Baz Ratner/File photo Acquire Licensing RightsGENEVA, Oct 2 (Reuters) - The World Health Organization (WHO) recommended on Monday the use of a second malaria vaccine to curb the life-threatening disease spread to humans by some mosquitoes. recommended the broad use of the world's first malaria vaccine called RTS,S," WHO chief Tedros Adhanom Ghebreyesus told a briefing in Geneva. "Today, it gives me great pleasure to announce that WHO is recommending a second vaccine called R21/Matrix-M to prevent malaria in children at risk of the disease." "GSK has always recognised the need for a second malaria vaccine, but it is increasingly evident that RTS,S, the first ever malaria vaccine and the first ever vaccine against a human parasite, set a strong benchmark," GSK said in a statement.

Persons: Baz Ratner, Tedros Adhanom Ghebreyesus, Tedros, Poonawalla, Takeda, Hanna Nohynek, Gabrielle Tétrault, Farber, Leroy Leo, Gareth Jones, Mark Potter Organizations: Lumumba, REUTERS, Rights, World Health Organization, WHO, Britain's University of Oxford, UNICEF, Serum Institute of India, Reuters, GSK plc, United Nations, GSK, Takeda Pharmaceuticals, Thomson Locations: Kisumu, Kenya, Geneva, Ghana, Malawi, Bengaluru

☆ Israeli cyber firm Legit Security raises $40 million in private funding
▼ + stars: | 2023-09-20 | by ( ) www.reuters.com time to read: +1 min

JERUSALEM, Sept 20 (Reuters) - Israeli cybersecurity firm Legit Security said on Wednesday it raised $40 million in a private funding round led by venture capital fund CRV. Since its founding in September 2020, Legit has raised a total of $77 million. It noted that its customer base includes brands such as Google, the NYSE, Kraft Heinz and Takeda Pharmaceuticals. On Tuesday, Israeli cyber firm Cato Networks said it raised $238 million in a late stage funding round, valuing the company at $3 billion. Israel has emerged as a global leader in cyber security in recent years.

Persons: TCV, Kraft Heinz, Takeda, Steven Scheer Organizations: Bessemer Venture Partners, Google, NYSE, Kraft, Takeda Pharmaceuticals, Cato Networks, Thomson Locations: CRV, Israel

☆ Here are Thursday's biggest analyst calls: Credit Suisse, Amazon, Block, First Republic, FedEx & more
▼ + stars: | 2023-03-16 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

Here are Thursday's biggest calls on Wall Street: JPMorgan reiterates Amazon as overweight JPMorgan said growth deceleration concerns are overdone. Stifel upgrades FedEx to buy from hold Stifel said FedEx shares are compelling at current levels. JPMorgan reiterates Credit Suisse as overweight JPMorgan said it's standing by shares of the banking giant. JPMorgan upgrades Motorola Solutions to overweight from neutral JPMorgan called the telecom equipment company "high quality." Bank of America upgrades Takeda Pharmaceuticals to buy from neutral Bank of America said called Takeda a "stable value stock."

Search resuls for: "Takeda Pharmaceuticals"

6 mentions found